Treatment of chronic type B hepatitis with recombinant alpha-interferon induces autoantibodies not specific for autoimmune chronic hepatitis.

Recombinant human alpha-interferon is now under intensive investigation as therapy for chronic Type B hepatitis. Recent reports have suggested that prolonged alpha-interferon therapy may induce autoimmune reactions. We have evaluated the problem of autoimmunity related to alpha-interferon therapy by testing for 15 different antibodies in the sera of 31 patients treated with alpha-interferon. No patient had autoantibodies before treatment; 27 (87%) of 31 patients developed at least one autoantibody. Eleven patients had antinuclear antibodies and 21 had smooth muscle antibodies, both of which usually developed during alpha-interferon therapy. In contrast, antibodies to endocrine organs such as thyroid microsomal, thyroglobulin and parietal cell antibodies arose in 12 patients, but usually several months after alpha-interferon treatment. The appearance of these autoantibodies did not correlate with disease activity or response to alpha-interferon. No patient developed autoantibodies specifically associated with autoimmune liver diseases such as liver kidney microsomal antibodies, autoantibodies to soluble liver antigen and the primary biliary cirrhosis specific subtypes of antimitochondrial antibodies. These results suggest that prolonged alpha-interferon therapy can induce autoantibody production and, in susceptible patients, may lead to autoimmune disorders.
AuthorsW J Mayet, G Hess, G Gerken, S Rossol, R Voth, M Manns, K H Meyer zum Büschenfelde
JournalHepatology (Baltimore, Md.) (Hepatology) Vol. 10 Issue 1 Pg. 24-8 (Jul 1989) ISSN: 0270-9139 [Print] UNITED STATES
PMID2737600 (Publication Type: Journal Article)
Chemical References
  • Autoantibodies
  • Interferon Type I
  • Recombinant Proteins
  • Antibody Specificity
  • Autoantibodies (immunology)
  • Autoimmune Diseases (immunology)
  • Chronic Disease
  • Endocrine Glands (immunology)
  • Female
  • Hepatitis (immunology)
  • Hepatitis B (immunology, therapy)
  • Humans
  • Interferon Type I (immunology, therapeutic use)
  • Male
  • Recombinant Proteins

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: